TCRN Travel story | Phil Haywood 2017 R2 Conference & Professional Development Grant

20 September 2017
Phil Haywood cropped photo

Phil Haywood has recently attended the iHEA (International Health Economics Association) conference as part of his professional development, to collaborate with and present to his fellow health economists.

Please read the interview below to find out more about his experience at the conference and the key take home messages that he would like to share with you all.

Could you tell us a bit about yourself and your research? 

I am in the final throes (hopefully) of my PhD. My PhD is about the costing of oncology treatments and using regularly collected information to determine the value and then the price. Hopefully, it will increase the accessibility of treatments by lowering the risk to the payer (government or hospitals).


Could you tell us about the conference you went to and why you chose to attend this conference? (What is unique or particularly important about it?)

The iHEA conference is the international conference of health economists.


What would be the most important outcomes of the conference for you – key learnings, or people you met, new collaboration, etc.

It was an opportunity to see other health economists present their ideas about oncology (and there were a few) as well as getting feedback about my research. The key opportunity came in feedback and networking. 


Could you tell us about your presentation at the conference?

It was a twenty-minute presentation about my research. There was an opportunity for questions from the floor, some of which focused on the technical details and others about the translational nature of the outcomes.


Were there any new knowledge or strategies from the conference you found interesting and possibly an interest of other TCRN members?

Yes, there was a large interest in screening in oncology and post-survivorship risk. One of the major issues was how to optimise screening and this did not have high quality clinical evidence to support it. Evidence about these issues from the TCRN and other transitional organisations would help inform health economists.


How can your research translate into improvements in patient care and clinical outcomes (Translational relevance)?

My research increases the understanding of financial risk that occurs to payers when they fund new treatments. Hopefully, this decreases the risk associated with new treatments and increases the number of treatments offered.


Could you tell us about your membership with the TCRN – what’s your involvement, how long have you been a member etc.?

I have been a member for five years. I was involved in the PhD program and then as a full member. It is incredibly useful, health economics is a collaborative process and interacting with patients, clinicians and other researchers allows us to see where our skills can add the most value.


You received funding to attend the conference – could you tell us about the difficulties of obtaining funding for these sorts of activities and how the TCRN fills this need?

Transitional research is important but often falls between specialist disciplines. It is sometimes difficult to get funding to attend specialist conferences for the purposes of disseminating transitional research. TCRN fills an important need by increasing the capacity to disseminate transitional research.